Market Closed - Nasdaq 21:00:00 08/05/2024 BST 5-day change 1st Jan Change
7.79 USD -3.83% Intraday chart for CVRx, Inc. -49.77% -75.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -3- DJ
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts MT
JPMorgan Downgrades CVRx to Neutral From Overweight, Adjusts Price Target to $13 From $36 MT
William Blair Downgrades CVRx to Market Perform From Outperform MT
Investors Await Fed Rate Decision as US Futures Trend Lower in Wednesday's Premarket MT
North American Morning Briefing : Traders Wait for Rate Decision, Powell; AMD Tumbles DJ
Transcript : CVRx, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Earnings Flash (CVRX) CVRX Reports Q1 Revenue $10.8M, vs. Street Est of $11.4M MT
CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024 CI
CVRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024 CI
CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024 CI
JPMorgan Raises CVRx's Price Target to $36 From $31, Keeps Overweight Rating MT
CVRx Q4 Net Loss Narrows, Revenue Climbs; Q1, Full-Year 2024 Revenue Guidance Set MT
Transcript : CVRx, Inc., Q4 2023 Earnings Call, Jan 25, 2024
CVRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (CVRX) CVRX Posts Q4 Revenue $11.3M, vs. Street Est of $11.1M MT
CVRx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Lake Street Adjusts CVRx Price Target to $35 From $32, Maintains Buy Rating MT
Transcript : CVRx, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
CVRx Shares Drop; CEO to Retire; Preliminary Q4, 2023 Revenue Top Consensus; Q1 Forecast Issued MT
CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer CI
Chart CVRx, Inc.
More charts
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.1 USD
Average target price
16.6 USD
Spread / Average Target
+104.94%
Consensus
  1. Stock Market
  2. Equities
  3. CVRX Stock
  4. News CVRx, Inc.
  5. Canaccord Genuity Adjusts Price Target on CVRx to $23 From $22, Maintains Buy Rating